Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company whose drug development pipeline relies on animal testing. The company’s lead investigational candidates, including serpinPC for hemophilia and LB101 for solid tumors, are in clinical trials following preclinical studies conducted in animal models. This use of animals in research is a standard, integral part of the company’s business model for bringing new therapeutics to market.

The provided evidence searches returned only generic regulatory risk disclosures from SEC filings, with no specific details on the nature or scale of Centessa’s animal testing activities. This lack of specific evidence, while not negating the inherent animal exploitation in pharmaceutical R&D, means the narrative cannot detail study types, species used, or animal numbers. The exclusion is based on the company's operational category as a drug developer, where animal testing is a foundational, non-optional component of the preclinical research process.